US Mulls TPP Re-entry, Critiques Japan Reforms
Executive Summary
President Trump has indicated the US may be interested in rejoining the Trans-Pacific Partnership free trade talks, but there would be multiple obstacles, not least whether strict US conditions could be met, including in the pharma IPR area. PhRMA meanwhile voices concerns over recent Japanese reforms.
You may also be interested in...
Could Contentious IPR Trade Terms Bloat Healthcare Costs, Sink Pharma’s Image?
Intellectual property rights terms in various trade agreements could have serious ramifications not just on healthcare costs but also on the legitimate trade of generic drugs between developing nations, say some experts. Pharma’s image may be at stake too.
Global IP Battle: Drug Pricing, Reimbursement Policies Take Center Stage
USTR's 2018 Special 301 Report moves two countries to Priority Watch List in part because of their pricing policies; AAM says focus should be on government reimbursement rather than extending IP protection.
Global IP Battle: Drug Pricing, Reimbursement Policies Take Center Stage
USTR's 2018 Special 301 Report moves two countries to Priority Watch List in part because of their pricing policies; AAM says focus should be on government reimbursement rather than extending IP protection.